Checking procalcitonin suitability for prognosis and antimicrobial therapy monitoring in burn patients

被引:18
作者
Cabral, Luis [1 ,2 ,3 ]
Afreixo, Vera [4 ]
Meireles, Rita [1 ,2 ]
Vaz, Miguel [1 ,2 ]
Chaves, Catarina [5 ]
Caetano, Marisa [6 ]
Almeida, Luis [7 ]
Paiva, Jose Artur [8 ,9 ]
机构
[1] Coimbra Univ Hosp Ctr CHUC, Unidade Queimados, Dept Plast Surg, Av Bissaya Barreto S-N, P-3000075 Coimbra, Portugal
[2] Coimbra Univ Hosp Ctr CHUC, Unidade Queimados, Burns Unit, Av Bissaya Barreto S-N, P-3000075 Coimbra, Portugal
[3] Univ Aveiro, Autonomous Sect Hlth Sci SACS, Aveiro, Portugal
[4] Univ Aveiro, CIDMA Ctr Res & Dev Math & Applicat, IBiMED, Inst Biomed, Aveiro, Portugal
[5] Coimbra Univ Hosp Ctr CHUC, Clin Pathol Dept, Coimbra, Portugal
[6] Coimbra Univ Hosp Ctr CHUC, Pharm Dept, Coimbra, Portugal
[7] Univ Porto, Fac Med, MedinUP, Dept Pharmacol & Therapeut, Porto, Portugal
[8] Ctr Hosp Sao Joao, Dept Emergency & Intens Care Med, Porto, Portugal
[9] Univ Porto, Grp Infeccao & Sepsis, Fac Med, Porto, Portugal
关键词
Burns; Sepsis; Procalcitonin; Prognosis; Antimicrobial stewardship; CRITICALLY-ILL PATIENTS; GUIDED ANTIBIOTIC-THERAPY; BLOOD-STREAM INFECTION; INTENSIVE-CARE UNITS; C-REACTIVE PROTEIN; SEPTIC SHOCK; SEVERE SEPSIS; RESPIRATORY-INFECTIONS; PLASMA PROCALCITONIN; SERUM PROCALCITONIN;
D O I
10.1186/s41038-018-0112-5
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Due to greater infection susceptibility, sepsis is the main cause of death in burn patients. Quick diagnosis and patient stratification, early and appropriated antimicrobial therapy, and focus control are crucial for patients' survival. On the other hand, superfluous extension of therapy is associated with adverse events and arousal of microbial resistance. The use of biomarkers, necessarily coupled with close clinical examination, may predict outcomes, stratifying patients who need more intensive care, and monitor the efficacy of antimicrobial therapy, allowing faster de-escalation or stop, reducing the development of resistance and possibly the financial burden, without increasing mortality. The aim of this work is to check the suitability of procalcitonin (PCT) to fulfill these goals in a large sample of septic burn patients. Methods: One hundred and one patients, with 15% or more of total body surface area (TBSA) burned, admitted from January 2011 to December 2014 at Coimbra Burns Unit (CBU), in Portugal were included in the sample. All patients had a diagnosis of sepsis, according to the American Burn Association (ABA) criteria. The sample was factored by survival (68 survivors and 33 non-survivors). The maximum value of PCT in each day was used for statistical analysis. Data were summarized by location measures (mean, median, minimum, maximum, quartiles) and dispersion measures (standard error and range measures). Statistical analysis was performed with SPSS (c) 23.0 IBM (c) for Windows (c). Results: There were statistically significant differences between PCT levels of patients from the survivor and non-survivor groups during the first and the last weeks of hospitalization as well as during the first week after sepsis suspicion, being slightly higher during this period. During the first 7 days of antimicrobial therapy, PCT was always higher in the non-survivor, still without reaching statistical significance, but when the analysis was extended till the 15th day, PCT increased significantly, rapidly, and steadily, denouncing therapy failure. Conclusion: Despite being not an ideal biomarker, PCT proved to have good prognostic power in septic burn patients, paralleling the evolution of the infectious process and reflecting the efficacy of antimicrobial therapy, and the inclusion of its serial dosing may be advised to reinforce antimicrobial stewardship programs at burn units; meanwhile, more accurate approaches are not available.
引用
收藏
页数:10
相关论文
共 96 条
[1]   Procalcitonin to Guide Duration of Antimicrobial Therapy in Intensive Care Units: A Systematic Review [J].
Agarwal, Rajender ;
Schwartz, David N. .
CLINICAL INFECTIOUS DISEASES, 2011, 53 (04) :379-387
[2]   Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination [J].
Angeletti, Silvia ;
Dicuonzo, Giordano ;
Fioravanti, Marta ;
De Cesaris, Marina ;
Fogolari, Marta ;
Lo Presti, Alessandra ;
Ciccozzi, Massimo ;
De Florio, Lucia .
DISEASE MARKERS, 2015, 2015
[3]  
[Anonymous], 2012, EFFECT SIZES RES UNI
[4]   Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States [J].
Balk, Robert A. ;
Kadri, Sameer S. ;
Cao, Zhun ;
Robinson, Scott B. ;
Lipkin, Craig ;
Bozzette, Samuel A. .
CHEST, 2017, 151 (01) :23-33
[5]   Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target [J].
Becker, Kenneth L. ;
Snider, Richard ;
Nylen, Eric S. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (02) :253-264
[6]   Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock A Randomized Clinical Trial [J].
Bloos, Frank ;
Trips, Evelyn ;
Nierhaus, Axel ;
Briegel, Josef ;
Heyland, Daren K. ;
Jaschinski, Ulrich ;
Moerer, Onnen ;
Weyland, Andreas ;
Marx, Gernot ;
Gruendling, Matthias ;
Kluge, Stefan ;
Kaufmann, Ines ;
Ott, Klaus ;
Quintel, Michael ;
Jelschen, Florian ;
Meybohm, Patrick ;
Rademacher, Sibylle ;
Meier-Hellmann, Andreas ;
Utzolino, Stefan ;
Kaisers, Udo X. ;
Putensen, Christian ;
Elke, Gunnar ;
Ragaller, Maximilian ;
Gerlach, Herwig ;
Ludewig, Katrin ;
Kiehntopf, Michael ;
Bogatsch, Holger ;
Engel, Christoph ;
Brunkhorst, Frank M. ;
Loeffler, Markus ;
Reinhart, Konrad .
JAMA INTERNAL MEDICINE, 2016, 176 (09) :1266-1276
[7]   Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial [J].
Bouadma, Lila ;
Luyt, Charles-Edouard ;
Tubach, Florence ;
Cracco, Christophe ;
Alvarez, Antonio ;
Schwebel, Carole ;
Schortgen, Frederique ;
Lasocki, Sigismond ;
Veber, Benoit ;
Dehoux, Monique ;
Bernard, Maguy ;
Pasquet, Blandine ;
Regnier, Bernard ;
Brun-Buisson, Christian ;
Chastre, Jean ;
Wolff, Michel .
LANCET, 2010, 375 (9713) :463-474
[8]   Procalcitonin for the early diagnosis of sepsis in burn patients: A retrospective study [J].
Cabral, Luis ;
Afreixo, Vera ;
Santos, Filipe ;
Almeida, Luis ;
Paiva, Jose Artur .
BURNS, 2017, 43 (07) :1427-1434
[9]   The Use of Procalcitonin (PCT) for Diagnosis of Sepsis in Burn Patients: A Meta-Analysis [J].
Cabral, Luis ;
Afreixo, Vera ;
Almeida, Luis ;
Paiva, Jose Artur .
PLOS ONE, 2016, 11 (12)
[10]  
Chamberlain RS, 2014, SURG SCI, V5, P48679